P/E ratio for Collegium Pharmaceutical (COLL)
P/E ratio as of April 2024 (TTM): -105
According to Collegium Pharmaceutical 's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -105.364. At the end of 2022 the company had a P/E ratio of -31.4.
P/E ratio history for Collegium Pharmaceutical from 2015 to 2023
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2022 | -31.4 | -437.35% |
| 2021 | 9.29 | -64.27% |
| 2020 | 26.0 | -185.95% |
| 2019 | -30.3 | 111.52% |
| 2018 | -14.3 | 92.22% |
| 2017 | -7.44 | 85.49% |
| 2016 | -4.01 | -76.36% |
| 2015 | -17.0 |
P/E ratio for similar companies or competitors
| Company | P/E ratio | P/E ratio differencediff. | Country |
|---|---|---|---|
 United Therapeutics UTHR | 12.3 | -111.64% | 🇺🇸 USA |
 Agile Therapeutics
AGRX | -0.0094 | -99.99% | 🇺🇸 USA |
 Horizon Therapeutics
HZNP | 60.6 | -157.49% | 🇮🇪 Ireland |
 KemPharm KMPH | -5.87 | -94.43% | 🇺🇸 USA |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.